Week 333 Review - Small rise into Christmas

December has been a bit of a disaster, but Santa woke up in the last week and the deficit between cost and value improved by £1,235 to £55,306 and total portfolio value crept back above £100k to £100,141,

No big fallers this week, but not a great deal of risers either.

TRX:Tissue Regenix climbed 6% after a torrid few weeks. They are still 62% down but there is hope that things will turn around as more surgical operations use their products.

Share of the Week is SBTX:SkinBioTherapeutics. After falling 24% in the 3 weeks since I bought them, they climbed 9% this week so are only 15% down now. News on new products expected early in the new year should see them re-rate.

Not exactly a stunning recovery

Still well below the trend line after a terrible year

Here's the ISA and shares portfolio after week 21 of year 7.

			Weekly Change
Cash	£37.05		+£0
Portfolio cost	£72,195.21		+£0
Portfolio sell value (bid price-commission)	£46,614.24	(-35.4%)	+£418.59
Potential profits	£2,255.29		+£40
Yr 7 Dividends	£22.16		+£0
Yr 7 Profit from sales	£3,664.29		+£0
Yr 7 projected avg monthly profit	£757.60	(20.6%)	-£37.88
Total Dividends	£1,365.31		+£0
Total Profit from sales	£27,788.23		+£0
Average monthly cash profit	£375.52	(10.2%)	-£1.13
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	65%		+0%

A small rise of £40 in potential profits with JLP:Jubilee Metals climbing a tiny amount. Portfolio value also up slightly with OPTI:Optibiotix unchanged. Long term performance still above target and year 7 performance twice target but with little prospect of being able to sell anything for a while.

Next week sees the removal of the low from 12 months ago, so the overall picture of 2021 will look grim.

Well below the trend line which will steepen next week, and in 4 weeks time we'll lose the brief blips when the account went into profit.

The SIPP looks like this after week 317 overall and week 5 of year 7.

			Weekly Change
Cash	£189.43		+£0
Portfolio cost	£80,392.42		+£0
Portfolio sell value (bid price - commission)	£52,097.13	(-35.2%)	+£773.42
Potential profits	£15.29		+£11.18
Yr 7 Dividends	£41.20		+£0
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£381.04		+£0
Yr 7 projected avg monthly profit	£351.37	(8.6%)	-£87.84
Total Dividends	£3,245.59		+£0
Total Interest	£0.20		+£0
Total Profit from sales	£24,105.67		+£0
Average monthly cash profit	£362.42	(8.8%)	-£1.15
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	54%		+0%

A better performance than the ISA with small increases throughout the portfolio, and there are more SBTX:SkinBioTherapeutics shares in this account, which was the biggest climber this week. Annual performance has rapidly dropped below long term average as we go past the first month of year 7 and the long term average dropped another 0.1% with no prospect of imminent improvement. Potential profits climbed £11 thanks to PAF:Pan African Resources, and their dividend should arrive next week.

Dangerously close to the injection line

This is going to look very grim next week as we plunge from profit to almost £30k down in 2021

The trading account looks like this after week 283 overall and week 23 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£944.23	(-60.2%)	+£43.42
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£15.28	(7.7%)	-£0.06
(Sold stocks profit + Dividends - Fees / Months)

A welcome change in fortune with all shares up slightly and DDDD:4D Pharma gaining 3% to recover some of the recent losses. 

A long way below the injection line

A very neat line, but unfortunately neatly downwards.

Just one more update left for 2021 and whatever happens next week it's going to be a depressing picture for 2021. Having to write about a consistently falling portfolio for a whole year has been very depressing. 

I've sold some of my best shares to try and boost my morale with some realised profits, and to provide a double boost by getting hold of some bargain shares. Unfortunately every time I do that, they drop further.

I think I have to accept that the sectors I have targeted are unloved by the markets this year. Gold, commodities and the microbiome are all struggling and undervalued, but I'm happy with all the companies I've invested in this year. Despite them all dropping 20-30% after me considering them as bargains, you can only hold back a share paying 6% dividends with a P/E ratio of 6 for so long, and many of my recent buys are in this situation. Crazy when the average P/E ratio is 15, and even higher in USA.

Let's hope 2022 reverses the form of 2021, else I'll be in deep trouble.

Week 332 Review - Santa is dead to me!

I thought last week was the turning point and the Santa rally had kicked in, but all last week's gains and more were wiped off the portfolio this week with huge drops in my biggest holdings. The deficit between cost and value widened by £6,987 to £56,641 and portfolio value dropped below £100k to £98,905. Bah humbug!!

JLP:Jubilee Metals was the biggest drop, falling 34% of my purchase price despite announcing that Colin Bird was stepping down as Chairman, which I would have expected to give the share price a boost. They are still 254% up and I must resist the temptation to sell any more.

SBTX:SkinBioTherapeutics was a genius purchase 3 weeks ago, falling 7%, 6% and now 11% since I bought them. Possibly my worst timed purchase ever, and I thought I was getting a bargain!

DDDD:4D Pharma continues to collapse despite news on the asthma drug this week. There were no negative surprises, but no mega clinical outcomes either, but I wasn't expecting a 6% drop.

TLOU:Tlou Energy also dropped 6%. I'm really confused as to why these have dropped so far since the announcement of securing finance for the electricity transmission lines. I was expecting it to re-rate upwards!

OPTI:Optibiotix lost all last week's gains, falling 3p and 5% to go 32% down, which on an investment of £100k is a lot. This despite news of 3 deals likely to bring £1m+ revenue each next year. I'm baffled.

A sliver of good news was the gold price starting to recover and go back above $1,800. That helped PAF:Pan African Resources climb 6% and get just about back in profit, and I got a nice dividend too.

Share of the Week for the second week in a row is BLU:Blue Star Capital, which climbed a mighty 22% this week and is now only 47% down. Momentum may very well take this back into profit and give me a dilemma whether to keep or sell. I don't like the company at all and it was a mistake to buy them, so I suspect I'll get rid as soon as I can. I only invested £500 so not going to gain or lose very much whatever I do.

Thank goodness we're still above the injection line, but back to a new 12 month low.

Desperate

Here's the ISA and shares portfolio after week 20 of year 7.

			Weekly Change
Cash	£37.05		-£50
Portfolio cost	£72,195.21		+£50
Portfolio sell value (bid price-commission)	£46,195.65	(-36.0%)	-£3,537.94
Potential profits	£2,215.29		-£300
Yr 7 Dividends	£22.16		+£0
Yr 7 Profit from sales	£3,664.29		+£0
Yr 7 projected avg monthly profit	£795.48	(21.6%)	-£46.92
Total Dividends	£1,365.31		+£0
Total Profit from sales	£27,788.23		+£0
Average monthly cash profit	£376.65	(10.2%)	-£1.43
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	65%		+0%

I got my 50 open offer shares in IES:Invinity Energy at 100p each, costing £50, and that also gave me 50 warrants due to mature over the next few years. Unfortunately the bid price is 90p so they are already 10% down, but they did reduce my weighted average to 397.9p. It will be a massive bonus if I ever get anything out of these shares as I was convinced they were going bust last year.

Potential profits dropped £300 thanks to the fall in JLP:Jubilee Metals and long term performance dropped by 0.1% to 10.2%, but at least that's still above target.

12-month low and not far off the injection line.

Dragging the trend line steeper down

The SIPP looks like this after week 316 overall and week 4 of year 7.

			Weekly Change
Cash	£189.43		+£41.20
Portfolio cost	£80,392.42		+£0
Portfolio sell value (bid price - commission)	£51,323.71	(-36.2%)	-£3,388.04
Potential profits	£4.11		+£3.11
Yr 7 Dividends	£41.20		+£41.20
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£381.04		+£0
Yr 7 projected avg monthly profit	£439.21	(10.7%)	-£87.08
Total Dividends	£3,245.59		+£41.20
Total Interest	£0.20		+£0
Total Profit from sales	£24,105.67		+£0
Average monthly cash profit	£363.57	(8.9%)	-£0.59
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	54%		+0%

A £41 dividend from PAF:Pan African Resources, profit up a tiny amount from the same company just about getting into profit and my iShares Physical Gold fund also being profitable. I'm not looking at the gigantic drop in portfolio value.

Just above the injection line, but if the Santa collapse continues we may cross it next week.

Really, really bad.

The trading account looks like this after week 282 overall and week 22 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£900.81	(-62.1%)	-£61.91
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£15.34	(7.8%)	-£0.05
(Sold stocks profit + Dividends - Fees / Months)

Could this possibly get any worse? Utter nightmare as everything falls yet again.

I had to change the axis else it would have gone below the bottom of the chart. Quite looking forward to a few weeks time when that red blip will be out of the way and it all looks much neater.

Now even sharper decline than the trend line.

I've given up hope of anything good happening before Christmas, as big news is unlikely to be announced next week. Let's hope 2022 is a bit kinder than 2021, as it's been a desperately bad year.

Week 331 Review - Optibiotix saves another poor week

Another pretty poor week for the majority of my portfolio, but OPTI:Optibiotix staged a mini rally which saved the day and clawed back £4,483 of the deficit to reduce it to £49,553. At one point the overall portfolio value dipped below £100k, but thankfully it climbed to £105,852 by the end of the week.

The gold miners had another bad week, with CEY:Centamin and PAF:Pan African Resources both dropping 5% as the gold price held below $1,800.

My new holding in SBTX:SkinBioTherapeutics did pretty badly too, dropping 6% after last week's 7% drop and re-affirming that I'm really bad at timing my purchases.

OPTI:Optibiotix climbed 3p which is 5% and almost won Share of the Week.

The Share of the Week award goes to BLU:Blue Star Capital which climbed 7% and seems to have a bit of momentum behind it. It will need a lot of momentum to claw back my 69% loss.

It looks like quite a small uptick on that chart

Still well below the trend line, but no longer the worst position of the year.

Here's the ISA and shares portfolio after week 19 of year 7.

			Weekly Change
Cash	£87.05		+£0
Portfolio cost	£72,145.21		+£0
Portfolio sell value (bid price-commission)	£49,683.59	(-31.1%)	+£2,498.90
Potential profits	£2,515.29		+£0
Yr 7 Dividends	£22.16		+£0
Yr 7 Profit from sales	£3,664.29		+£0
Yr 7 projected avg monthly profit	£842.40	(22.9%)	-£46.80
Total Dividends	£1,365.31		+£0
Total Profit from sales	£27,788.23		+£0
Average monthly cash profit	£378.08	(10.3%)	-£1.14
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	65%		+0%

A very quiet week, with JLP:Jubilee Metals flat so no change in potential profits. The big increase in value is mostly OPTI:Optibiotix, and long term performance still above 10% target.

Well it's a start, but still worse than it was 12 months ago.

Still a long way below the trend line

The SIPP looks like this after week 315 overall and week 3 of year 7.

			Weekly Change
Cash	£148.23		-£112.10
Portfolio cost	£80,392.42		+£222.45
Portfolio sell value (bid price - commission)	£54,711.75	(-31.9%)	+£2,007.15
Potential profits	£1.00		-£81.93
Yr 7 Dividends	£0		+£0
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£381.04		+£113.35
Yr 7 projected avg monthly profit	£526.29	(12.8%)	-£17.57
Total Dividends	£3,204.39		+£0
Total Interest	£0.20		+£0
Total Profit from sales	£24,105.67		+£113.35
Average monthly cash profit	£364.16	(8.9%)	+£0.41
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	54%		+0%

I sold my 665 WHR:Warehouse REIT shares for £113.34 (10.8%) profit because I had already qualified for the dividend and I wanted to buy more OPTI:Optibiotix while they were so cheap. I bought another 2,664 shares at 41.9898p costing £1,127.56 which brought my average SIPP price down just below 60p a share and my total OPTI holding to 174,069. I've set a target of 150,000 shares as my long term holding so hopefully the additional 24,069 will give me a little room for profit taking if they ever get into profit.

I also bought 4 more units of the iShares Physical Gold fund as part of my monthly savings plan, at 2616.854p costing £106.17.

Year 7 performance is good but I won't keep it up, and long term performance is still under target but I have nothing left to sell.

As with the ISA, there's a long way to go.

Still below the trend line, but not as bad as the ISA.

The trading account looks like this after week 281 overall and week 21 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£962.72	(-59.4%)	-£22.64
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£15.39	(7.8%)	-£0.05
(Sold stocks profit + Dividends - Fees / Months)

All shares were down a few percent yet again, with DDDD:4D Pharma and HUM:Hummingbird Resources both down by 58% now, and IQE:IQE down by 71%. That's what you call a proper disaster of an account! I know my mistake was failing to sell all of them as soon as they went 15% down. I think I'm incapable of doing it, which means I'm probably incapable of trading shares. I'll keep this account going to remind me of that fact.

Ouch!

It's a spectacularly consistent trend line. Twelve months of absolute misery.

I've given up hope of any news from DDDD:4D Pharma before Christmas, and I'm getting increasingly nervous about my investment there. I may have been foolish sinking £10k into them as it's a lot to lose and I think there's still quite a bit of risk.

I think there's much less risk with OPTI:Optibiotix because of the low recurring costs, so I'm still not nervous about my investment there despite it being an insanely large percentage of my portfolio. I've had 6 years to convince myself I'm wrong, and I'm still as convinced as ever that the company is something special that doesn't come along very often. The foundations of IP and commercial bulk production are very strong, and every week we hear of more sales. Sooner or later they will tip us into profit, and that's before SweetBiotix and the microbiome modulators even get started. 

Week 330 Review - Christmas misery continues

It's not getting any better! This week saw the deficit between cost and value widen by £4,821 making the losses £17,418 over the last 3 weeks. Santa rally??? The deficit is now £54,037 and total portfolio value is only just holding up above £100k at £101,258.

Biggest loser was my SIPP holding of TLOU:Tlou Energy which fell by 12%, which was a mystery given they secured financing for the transmission lines, which I thought would generate a re-rate upwards. There were misleading bulletin board posts about death spiral loans which could have spooked some people, but surely not enough would be fooled to cause such a big drop? I suspect these may stagnate until the hydrogen production facility is build early next year, as that will start to generate some income.

SBTX:SkinBioTherapeutics was my next biggest lose, which is depressing given I only bought them this week! I have said for some time that I will buy back in when they go under 50p, and that happened the day before results day. I sold 5,000 JLP:Jubilee Metals shares and added £255 so I could buy 2,116 shares at 47.245p costing £1,011.65. On results day they dropped below 40p and ended the week at 45p bid price, so most of the deficit is spread. 

When the price collapsed following results I sold my CAML:Central Asia Metals holding and bought 3,180 SBTX shares at 45.22p costing £1,449.95. Those are only 2% down so a lot less distressing. I'll buy back into CAML:Central Asia Metals with my next transfer in February, in time for dividend day in April.

ASY:Andrews Sykes Group has been pretty static since I bought them, but dropped 6% this week for no reason other than the market being rubbish.

CMCL:Caledonia Mining and HUM:Hummingbird Resources also dropped 6% as the price of gold dipped below $1,800, and PAF:Pan African Resources dropped 5% but went ex-dividend so has a better excuse. Blackrock World Gold Fund also dropped 5% to go into loss.

OPTI:Optibiotix dropped 2p despite news of a new deal for LeanBiome which will result in £1m new revenue in 2022. So a 25%+ increase in revenue causes a share price drop? Well I never!

Share of the Week is one of the few that gained anything this week. JLP:Jubilee Metals climbed 24% of my purchase price following superb results. I feel a tad guilty that I rewarded them by selling some more.

Thankfully above the injection line

Devastating

Here's the ISA and shares portfolio after week 18 of year 7.

			Weekly Change
Cash	£87.05		+£76.90
Portfolio cost	£72,145.21		+£796.45
Portfolio sell value (bid price-commission)	£47,184.69	(-34.6%)	-£2,311.81
Potential profits	£2,515.29		-£359.80
Yr 7 Dividends	£22.16		+£0
Yr 7 Profit from sales	£3,664.29		+£568.35
Yr 7 projected avg monthly profit	£889.20	(24.1%)	+£97.26
Total Dividends	£1,365.31		+£0
Total Profit from sales	£27,788.23		+£568.35
Average monthly cash profit	£379.22	(10.3%)	+£6.57
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	65%		+1%

Profit from sales increased by £568 thanks to selling 5,000 JLP:Jubilee Metals at 15.91p to make £568.35 (250%) profit. Potential profits only dropped by £359 as JLP went up after my sale. I also added another £55 cash as there's an open offer for IES:Invinity Energy coming up and it's a good chance to reduce my average price so I'll take part, as there's hope things could start happening with some bigger orders coming in.

Long term performance improved by £6 a month and is still healthy at 10.3%, with year 7 projected profit even better at 24%, but that won't last as I don't have much more JLP left to sell. We won't mention the £2,311 drop in portfolio value...

Worryingly close to the injection line

On the cusp of having to change the lower limit of the chart.

The SIPP looks like this after week 314 overall and week 2 of year 7.

			Weekly Change
Cash	£260.33		+£85.44
Portfolio cost	£80,169.97		+£302.25
Portfolio sell value (bid price - commission)	£52,482.15	(-34.5%)	-£2,485.56
Potential profits	£82.93		-£263.83
Yr 7 Dividends	£0		+£0
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£267.69		+£267.69
Yr 7 projected avg monthly profit	£543.86	(13.3%)	+£543.86
Total Dividends	£3,204.39		+£0
Total Interest	£0.20		+£0
Total Profit from sales	£23,992.32		+£267.69
Average monthly cash profit	£363.75	(8.9%)	+£2.31
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	54%		+0%

Another huge drop in portfolio value, and the sale of CAML:Central Asia Metals only increased the long term performance by 0.1% so we're still below 10% target. The CAML sale was 600 shares at 237.89p to make £267.70 (24%) profit. I hate being out of these and want to buy back asap, but I really wanted to get into SBTX:SkinBioTherapeutics before they announce any of the Croda deals, as I think they are imminent.

Cash increased as there was a £120 injection to cover my monthly iShares Physical Gold fund purchase.

Also very close to the injection line

Desperate

The trading account looks like this after week 280 overall and week 20 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£985.36	(-58.5%)	-£24.55
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£15.44	(7.8%)	-£0.06
(Sold stocks profit + Dividends - Fees / Months)

DDDD:4D Pharma increased slightly this week, but the rest dropped, so another £24 gone and overall down by 58% which is pretty shocking.

It just keeps getting worse.

Bang on the trend line and following it relentlessly downwards.

It feels so nice to be back invested in SBTX:SkinBioTherapeutics, as I really like the company. I was right to avoid investing at 60p, as it was over-priced, but I jumped in too quick as it dropped below 40p mid-week. However, it soon climbed back again so I don't really mind. I got in below 50p which is the important thing. 

I'm expecting really good news for DDDD:4D Pharma, OPTI:Optibiotix and SBTX:SkinBioTherapeutics before Christmas, so there is still a good chance of a Santa rally, despite one of the worst 3 week periods in my portfolios history.

Week 329 Review - The nightmare continues with greater losses than last week

What an utterly depressing week. You can tell it's bad when my biggest riser was 0%. The crash on Friday caused by the new strain of Covid did the most damage, and although the gold price rebounded, it wasn't enough to undo all the big drops from earlier in the week. The deficit between cost and value widened by £7,607 to £49,215 and portfolio value dropped to £104,819. If it drops below £100k I'm going to have a very miserable Christmas.

JLP:Jubilee Metals was the worst performer dropping 14% of my purchase price, but it was a relatively small percentage of the current price.

IQE:IQE gave a trading statement that was effectively a profit warning, and despite all the chip manufacturers gaining massively due to chip shortages, IQE is managing to do even worse than usual and fell 10% this week.

I'll cover all the gold mines together as they all dropped early in the week, but failed to catch up after the price of gold went back above $1,800. PAF:Pan African Resources dropped 12%, Blackrock World Gold Fund dropped 7%, CEY:Centamin dropped 6% and POLY:Polymetal also dropped 6%.

DDDD:4D Pharma is my 2nd biggest holding and the lack of news coupled with a forced large seller saw the price drop 8% making these worth half what I bought them for.

My largest holding OPTI:Optibiotix dropped 5% to the lowest they have been for a long time. News is expected before Christmas, but at this rate it's only going to lift us back to the 50p range and will still be losing money.

There's no Share of the Week because nobody deserved it. My highest risers were CAML:Central Asia Metals and IGG:IG Group, but they both climbed by less than 1% so there's absolutely no silver lining to my cloud of misery.

Getting dangerously close to the injection line

It's very difficult to keep one's pecker up when the relentless decline has been going on for almost a year.

Here's the ISA and shares portfolio after week 17 of year 7.

			Weekly Change
Cash	£10.15		+£0
Portfolio cost	£71,348.76		+£0
Portfolio sell value (bid price-commission)	£48,700.05	(-31.7%)	-£3,560.53
Potential profits	£2,875.09		-£150.00
Yr 7 Dividends	£22.16		+£0
Yr 7 Profit from sales	£3,095.94		+£0
Yr 7 projected avg monthly profit	£791.94	(21.6%)	-£49.50
Total Dividends	£1,365.31		+£0
Total Profit from sales	£27,219.88		+£0
Average monthly cash profit	£372.65	(10.2%)	-£1.13
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	64%		+0%

Massive losses and potential profits down £150 as JLP:Jubilee Metals dropped. The only ray of light is that my long term performance is above 10% target, but it's hard to get enthused when your portfolio is down by 31%.

Plunging towards the injection line

After getting so close to crossing the trend line, now we're well below it.

The SIPP looks like this after week 313 overall and week 1 of year 7.

			Weekly Change
Cash	£174.89		+£0
Portfolio cost	£79,867.72		+£30.00
Portfolio sell value (bid price - commission)	£54,665.46	(-31.6%)	-£3,899.75
Potential profits	£346.76		-£146.49
Yr 7 Dividends	£0		+£0
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£0		+£0
Yr 7 projected avg monthly profit	£0	(0%)	+£0
Total Dividends	£3,204.39		+£0
Total Interest	£0.20		+£0
Total Profit from sales	£23,724.63		+£0
Average monthly cash profit	£361.44	(8.8%)	-£1.16
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	53%		+0%

The portfolio cost went up £30 because rather annoyingly Hargreaves Lansdown keeps automatically investing my tax rebate, so given the same thing will happen next month there's no point in me selling the gold fund yet. The £30 bought another 1.26 units of Blackrock World Gold fund at 2380.95238p so the good news was that the purchase was made just after the gold price dropped.

This is the first week of year 7 so all the annual stats have been set to zero. Potential profits dropped but not by as much as I feared, but massive drop in value across the board.

This would be less depressing if the cost line wasn't going up so much. The next chart will be more revealing

Crashing back below the trend line. What an utterly rubbish year!

The trading account looks like this after week 279 overall and week 19 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£1,009.91	(-57.5%)	-£147.65
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£15.50	(7.8%)	-£0.06
(Sold stocks profit + Dividends - Fees / Months)

One of the biggest ever weekly drops. Was it really just a few weeks ago I was suggesting my DDDD:4D Pharma holding might get into profit soon?

I'll have to adjust the chart to show a lower value next week if we drop any further

A brief dalliance above the trend line didn't last long.

I'm too miserable to write any more.